Yiming Biotech announced that the new inhibitory antibody IO-108 targeting LILRB2 (ILT4) has completed the first case of drug delivery to patients with advanced solid tumors in the United States.

Recent popular reports from Yimaike ★Case sharing of cell therapy process innovation-Challenges in cell therapy production and the application of countercurrent centrifugation technology in closed productionYimai Meng broke the news ★ Conference invitation | Sartorius co-organized the first WuXi Gene Therapeutic Technology Forum October 15, 2021/MedClub News/--Palo Alto, USA, Hangzhou, China, in the clinical stage, dedicated to the development of targeted immunosuppressive myeloid immune checkpoints and innovative cancer immunotherapy organisms The pharmaceutical company Immune-Onc Therapeutics, Inc.
("Yiming Bio") recently announced that the first human clinical trial of IO-108 has completed the first patient administration in the United States
.

IO-108 is a new inhibitory antibody targeting the leukocyte immunoglobulin-like receptor B2 (LILRB2, also known as ILT4) of the myeloid immune checkpoint
.

IO-108 can bind to LILRB2 with high affinity and specificity, and block the interaction of ligands HLA-G, ANGPTLs, SEMA4A and CD1d related to cancer immunosuppression in the tumor microenvironment
.

In preclinical studies, the treatment of multiple human primary immune cell systems containing myeloid cells with IO-108 can enhance their pro-inflammatory response to multiple stimuli related to anti-tumor immunity
.

As a single agent, IO-108 can reverse the anti-inflammatory phenotype of myeloid cells due to "tumor regulation" and promote the differentiation of monocytes into pro-inflammatory dendritic cells
.

Not only that, IO-108 can also enhance the activating effect of PD-1 blocking antibodies on CD4+ T cells when co-cultured with allogeneic macrophages
.

In mouse models, IO-108 can inhibit the growth of solid tumors and enhance T cell responses
.

These data together show that IO-108 combined with standard immunotherapy and/or other immunogenerating therapies has cumulative or synergistic benefits in the treatment of solid tumors that are resistant or sensitive to T cell checkpoint inhibitors Potential
.

About LILRB2 (ILT4) LILRB2, also known as ILT4, is mainly expressed on myeloid cells, including monocytes, dendritic cells, macrophages and neutrophils
.

In solid tumors, LILRB2 can interact with related ligands HLA-G, ANGPTLs, SEMA4A and CD1d in the tumor microenvironment (TME), causing myeloid cells to promote tumors (allowing or promoting tumor growth) and enhancing tumor immune escape
.

About Yiming Biological Yiming Biological is a biopharmaceutical company in the clinical research and development stage, focusing on cancer immunotherapy, and is committed to finding and developing new myeloid immune checkpoint inhibitors for cancer patients
.

The company's goal is to discover and develop innovative new biological drugs that can relieve immunosuppression in the tumor microenvironment by transforming unique scientific insights into myeloid cell biology and immunosuppressive receptors
.

The company has built a number of promising product pipelines around the myeloid immune checkpoint-leukocyte immunoglobulin-like receptor subfamily B (LILRB), using the synergistic effect of the biological platform
.

These include two world-first innovative drugs in phase I clinical development: IO-108 for solid tumors, treatment of acute myeloid leukemia (AML) and chronic myeloid-monocytic leukemia (CMML), targeting LILRB4 (and Called ILT3) IO-202
.

The company is also actively planning the efficacy evaluation of IO-202 in solid tumors
.

In October 2020, the U.
S.
Food and Drug Administration (FDA) granted IO-202 orphan drug designation
.

In addition, the company's product pipeline also includes a new antibody drug IO-106 targeting LAIR1, as well as a number of undisclosed projects targeting solid tumors and hematological malignancies
.

Yiming Biology and The University of Texas, Albert Einstein College of Medicine and Memorial Sloan Kettering Cancer Center, etc.
The institution has formed a long-term strategic research partnership, and has established a series of proprietary experimental models, methods and tools to conduct biological investigations and transform cutting-edge research into the development of innovative therapies
.

Yiming Bio is headquartered in Palo Alto, California, and has established a diversified team with rich experience in the field of drug development and deep qualifications in the world's top biotechnology companies
.

For more information about the company, please visit https:// or follow the company’s Twitter and LinkedIn accounts
.